Sandoz Introduces High-Concentration Formulation of Hyrimoz in Europe
Shots:
- The company has launched Hyrimoz (Biosimilar, adalimumab) citrate-free high-concentration formulation (100 mg/mL) in Europe indicated for all conditions treated by reference medicine Humira.
- In contrast to the existing Hyrimoz (50 mg/mL) formulation, Hyrimoz citrate-free HCF, a revised formulation (100 mg/mL) that provides a 50% reduction in injection volume, potentially reducing the number of injections needed for patients who require 80 mg/mL or higher dose, the formulation is administered using the well-known Hyrimoz SensoReady pen
- This launch will strengthen the company’s biosimilar portfolio in its immunology pipeline
Ref: Globenewswire | Image: sandoz
Related News:- Sandoz to Launch Hyrimoz High-Concentration Formulation Biosimilar in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
